Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.
about
Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switchControl of the SOST bone enhancer by PTH using MEF2 transcription factorsControl of RANKL gene expressionA review of anabolic therapies for osteoporosisCatabolic and anabolic actions of parathyroid hormone on the skeletonInterleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actionsOsteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease.Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis.The potential of p38 MAPK inhibitors to modulate periodontal infections.Parathyroid hormone: anabolic and catabolic actions on the skeletonImipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived MicrovesiclesHDAC4 integrates PTH and sympathetic signaling in osteoblasts.Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in miceEffects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal womenDeficiency of osteoblastic Arl6ip5 impaired osteoblast differentiation and enhanced osteoclastogenesis via disturbance of ER calcium homeostasis and induction of ER stress-mediated apoptosis.Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancersParathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer.Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials.Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.Nmp4/CIZ suppresses the response of bone to anabolic parathyroid hormone by regulating both osteoblasts and osteoclasts.Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor.Wnt/β-catenin signaling is differentially regulated by Gα proteins and contributes to fibrous dysplasia.Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor.The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice.A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.Role of DNA methylation in the regulation of the RANKL-OPG system in human bone.Phosphate: known and potential roles during development and regeneration of teeth and supporting structures.Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor.Osteocyte RANKL: new insights into the control of bone remodelingMicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass.The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.Osteocyte control of osteoclastogenesis.Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorptionRoles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease.Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice
P2860
Q24302076-B62BE67E-FC87-4A35-A0C5-31F6DF459829Q24337339-864D5EE0-F040-4252-8B69-A7CA8C909BAEQ24619669-6EE4C1D0-ADAE-42C3-9B8D-5535E17642D9Q24797842-E12BF09C-58A5-4133-A93D-94EF23A339D8Q26828873-C04DC605-6E23-4274-8014-35B99CC0234AQ28580087-04592E77-F408-44A5-8F1D-A6037C3FE5A0Q30416347-C9982BA5-8943-4B6D-A864-8DD310311253Q30494322-690F6CCA-1980-4EC5-87C4-FB9B24F67316Q33606744-89F871B5-EAE4-4669-9B44-ED123031CFFDQ33609126-EECE4BB8-E431-4050-A386-7B020C580F8EQ33755136-B105A582-DF1A-4404-8EC1-D7125DF88858Q33797044-5791C797-7885-456A-931A-17ABED2CC905Q33874504-D47B8C26-C967-4569-90ED-0A7493FD0267Q34017216-2369FC73-DD91-42EB-BEF2-4F053675EB5FQ34090139-6B3F544D-7AFA-4FE8-A657-AE7A9EF9B135Q34262453-E11512F3-47F4-408F-8B17-473D61C11574Q34541607-C9C1050F-2E3F-49C2-9712-606B5A4117A3Q35071128-090A8658-8264-41FC-BEDC-40AC4E9EFF38Q35071181-A6B15BE5-E323-4F4C-B6DA-9CCFE912D70FQ35165694-B1594D97-87C2-420D-A30E-0440C88C9CD3Q35229844-00859B28-61E9-4F6D-8FA0-82D9DEDE728FQ35229920-8BA8EF78-2B3C-484F-918A-B48C52E2E9F6Q35432065-C44F32F5-454E-46B5-8FC0-FDE5EF7612D7Q35641926-75804E80-3DC5-47FF-9DC6-53FF2AE31EC7Q35647471-06ECC3BA-AC12-4F50-BFD7-9668B0645C05Q35658848-EBEF26D2-926E-40C7-82AD-67596BEAAFAFQ35744006-A22858F3-12BC-4B2C-90CE-1E25CEBBE42CQ35779222-EAC6DC93-EEE8-4435-B512-AE55B813788AQ35860566-BD2D8882-039A-4F0B-8D03-0A0C8DDE4C21Q35916106-E974E420-E0EB-4CB3-B4DA-60D1F448748FQ35920063-1B772969-16A1-4F6B-8855-70FB98EC5485Q35983075-BDBD6C40-1696-4B21-848B-91C5FE9DEEF6Q36253514-10ADB10F-F7C8-4C31-9811-CECD69D3EF93Q36326306-4F0D9947-AC7D-43C1-95F3-A84BCB827A52Q36372606-BF0DF9CC-72B6-4EA7-A5DA-C2CDBA2EE405Q36494408-0AA151AE-0C8D-4EC6-A417-97AED19D0A68Q36514172-1ED75436-810B-4B9A-AFA3-0974C6E34DE4Q36677744-C61CC34A-F785-4EF3-AFC0-F4FA069E4955Q36703949-3C60344B-4A61-440F-ADB2-9EEBDD3C987CQ36808470-4594CF3E-C4C0-4831-9D83-4D8579C305DC
P2860
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Parathyroid hormone stimulates ...... ponse element-binding protein.
@en
type
label
Parathyroid hormone stimulates ...... ponse element-binding protein.
@en
prefLabel
Parathyroid hormone stimulates ...... ponse element-binding protein.
@en
P2093
P2860
P356
P1476
Parathyroid hormone stimulates ...... ponse element-binding protein.
@en
P2093
Charles A O'Brien
Robert L Jilka
Stavros C Manolagas
P2860
P304
48868-48875
P356
10.1074/JBC.M208494200
P407
P577
2002-10-02T00:00:00Z